More importantly, the combination of selumetinib and cetuximab failed to achieve positive results in a clinical trial in refractory metastatic CRC patients with KRAS mutations [30, 101] To date, binimetinib is the only MEK inhibitor permitted by the Food and Drug Association for clinical use in mCRC. This evidence concerns the gene KRAS and colorectal carcinoma.